Ultragenyx Pharmaceutical (RARE) Return on Sales (2016 - 2026)

Ultragenyx Pharmaceutical (RARE) has 11 years of Return on Sales data on file, last reported at 0.01% in Q1 2026.

• On a quarterly basis, Return on Sales changed 0.0% year-over-year to 0.01% in Q1 2026; TTM through Mar 2026 was 0.01%, a 0.0% change from a year earlier, with the FY2025 full-year figure at 0.01%, changed 0.0% from the prior year.
• Return on Sales for Q1 2026 stood at 0.01%, down from 0.01% in the prior quarter.
• Over the last five years, Return on Sales for RARE reached as high as 0.01% in Q4 2025 and fell as low as 0.03% in Q3 2022.
• Historically, Return on Sales has averaged 0.01% across 5 years, with a median of 0.01% in 2026.
• Across the five-year window, Return on Sales fell 5 bps in 2022 and grew 1 bps in 2023, its largest moves.
• Year by year, Return on Sales stood at 0.01% in 2022, then jumped by 35 bps to 0.01% in 2023, then rose by 19 bps to 0.01% in 2024, then advanced by 25 bps to 0.01% in 2025, then sank by 130 bps to 0.01% in 2026.
• Per Business Quant data, the three most recent Return on Sales figures were 0.01% in Q1 2026, 0.01% in Q4 2025, and 0.01% in Q3 2025.